|Click on "►" to expand:|
 BRAND NAMES
 MECHANISM OF ACTION
Eperisone is a centrally acting muscle relaxant, it reduces skeletal muscular spasticity via its actions within the CNS and relaxes vascular smooth muscle directly. It primarily acts at the spinal cord level and gamma motor neurons therefore it suppresses spinal reflexes and reduces the sensitivity of muscle spindles. Eperisone also enhances blood circulation due to calcium-antagonistic actions on vascular smooth muscle, this action is noteworthy since a muscle contracture may compress the small blood vessels and induce an ischemia leading to release of nociceptive compounds.
Improvement of myotonic conditions caused by the following diseases:
- Neck-shoulder-arm syndrome, scapulohumeral periarthritis and low back pain
- Spastic paralysis caused by the following diseases:
- Cerebrovascular disorders
- spastic spinal paralysis
- spastic multiple sclerosis
Adults: Usually 150-300 mg per day in three divided doses after each meal. The dosage should be adjusted depending on the patient age and severity of symptoms.
Hypersensitivity to Eperisone
- Eperisone should be administered with care in patients with hepatic function disorder (Eperisone may aggravate hepatic function).
- Weakness, light-headedness, sleepiness or other symptoms may occur during treatment with Eperisone. In the event of such symptoms, the dosage should be reduced or treatment
discontinued. Patients should be cautioned against engaging in potentially hazardous activities requiring alertness, such as operating machinery or driving a car.
 PREGNANCY AND LACTATION
Eperisone should only be used in pregnant women if the expected therapeutic benefits are evaluated to outweigh the possible risks of treatment. The safety of Eperisone has not been established in pregnant women. The drug should not be used during lactation.
 SIDE EFFECTS
Eperisone may cause side effects in some patients including: Sleepiness, insomnia, headache and numbness in the extremities, Nausea/vomiting, anorexia, stomach discomfort, abdominal pain, diarrhea, constipation and thirst, weakness, light-headedness, generalized fatigue and hot flushes
- Clinically significant adverse reactions (incidence unknown):
- Shock and anaphylactoid reactions may occur: Patients should be carefully observed and in the event of symptoms such as redness, itching, urticaria, edema of the face or other parts and dyspnea etc., treatment should be discontinued and appropriate measures should be taken.
- Toxic epidermal necrolysis (TEN) and oculomucocutaneous syndrome (Stevens-Johnson syndrome): Because Eperisone may cause serious skin disorders including Toxic Epidermal Necrolysis (TEN) and oculomucocutaneous syndrome etc., patients receiving this medication should be carefully monitored for symptoms such as fever, erythema, blisters, itchiness, ocular hyperemia, and stomatitis. If any of these symptoms appear, administration should be discontinued, and appropriate measures should be taken.